Dr. Charles Carl Calenda, MD

Dr. Calenda practices at Calenda Eyecare Center in Warren, Rhode Island.

Dr. Calenda's NPI, 1275557720, was assigned on July 27, 2006. Dr. Calenda graduated from UNE College of Osteopathic Medicine in 2025. Dr. Calenda holds Rhode Island license MD0605.

Dr. Calenda's primary practice is Calenda Eyecare Center, at 639 Metacom Ave, Warren, RI 02885 in Bristol County. The practice phone is (401) 737-2200.

Dr. Calenda's primary practice is Calenda Eyecare Center in Warren, Rhode Island. Dr. Calenda is also affiliated with Roger Williams Medical Center. Dmand AI also links Dr. Calenda to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Calenda practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Calenda's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Calenda's licenses on file in 2 states: Rhode Island and Massachusetts.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Calenda treats.

CMS data shows 1,866 Medicare services from Dr. Calenda across 15 procedure codes in 2024, for 662 Medicare patients. Medicare paid $122,928 for them.

CMS counts 662 Medicare patients who saw Dr. Calenda in 2024. The largest group is 75 to 84, with 315 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.05, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Calenda's median patient age at 68, with 57% women.

In 2024, Dr. Calenda wrote 1,831 Medicare Part D claims for 392 patients. 77% of them were for generic drugs. CMS names the drug for 1,765 of them, across 17 drugs with 11 or more claims each, at $121,546 in total drug cost. In 2023, CMS named 1,715 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 21 out of 100 for Dr. Calenda for performance year 2024, reported individually. Dr. Calenda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 48 procedures of cataract surgery by Dr. Calenda, more than 62% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Calenda, published from 2016 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Mice, Inbred C57BL, Hepatitis, Alcoholic and Diet, High-Fat. Dr. Calenda has published most often in Hepatol Commun. Dr. Calenda's most frequent co-authors are Jan Petrasek, MD, PhD, Jaspreet Singh Ubhi, MD and Timea Csak, MD, PhD.

CMS Open Payments shows 40 general payments to Dr. Calenda from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $1,107.

Dr. Calenda graduated from UNE College of Osteopathic Medicine in 2025. Dr. Calenda is a member of American Society of Nephrology.

Dr. Calenda is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.